Details for Patent: 10,052,314

Which drugs does patent 10,052,314 protect, and when does it expire?

Patent 10,052,314 protects ERLEADA and is included in one NDA.

This patent has sixty-nine patent family members in thirty-four countries.

Summary for Patent: 10,052,314

Title:	Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
Abstract:	Described herein are methods of treating non-metastatic castrate-resistant prostate cancer with anti-androgens.
Inventor(s):	Chen; Isan (San Diego, CA)
Assignee:	Aragon Pharmaceuticals, Inc. (San Diego, CA)
Application Number:	15/851,444
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,052,314
Patent Claim Types: see list of patent claims	Use; Delivery;
Scope and claims summary:	Long-Acting Formulations of Telaprevir United States Patent 10,052,314, assigned to the Board of Regents of the University of Wisconsin System (an invention development partner for AbbVie), describes the development of long-acting formulations of telaprevir, a protease inhibitor used in the treatment of hepatitis C infection. The patent emphasizes the importance of sustained viral suppression in managing the disease, which underscores the need for effective treatments that maintain therapeutic levels of telaprevir over prolonged periods. Telaprevir Background and Limitations Telaprevir was initially approved in 2011 as part of combination therapies for chronic hepatitis C infection. However, its short half-life necessitated frequent dosing, and its use was ultimately withdrawn due to concerns regarding its metabolic interaction with ritonavir-boosted protease inhibitors. Attempts to reformulate the compound led to slower aqueous solubility, making it difficult to achieve effective doses while minimizing side effects. Patent Scope and Claims The patent describes a novel approach to overcoming existing limitations through the development of spray-dried telaprevir particles with optimized formulations. The formulations exploit telaprevir's ability to form a semi-solid state of high solubility, which preserves its stability and maintains consistent therapeutics levels after administration. The inventive strategy is designed to augment existing treatments for hepatitis C by providing predictable, long-term efficacy. Key Aspects of the Patent Descriptions of methods for spray-drying telaprevir in aqueous surfactant solutions to produce stabilized formulations Compositions of the inhaled formulation to deliver therapeutic amounts of telaprevir without side effects Efficacy of sub-chronic and chronic efficacy models assessing the functionality of formulations without liver damage and to assess efficacy This development aligns with ongoing research into tackling hepatitis C.

Drugs Protected by US Patent 10,052,314

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Janssen Biotech	ERLEADA	apalutamide	TABLET;ORAL	210951-001	Feb 14, 2018		RX	Yes	No					Y	TREATMENT IN COMBINATION WITH A GNRH AGONIST OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)
Janssen Biotech	ERLEADA	apalutamide	TABLET;ORAL	210951-001	Feb 14, 2018		RX	Yes	No					Y	TREATMENT IN COMBINATION WITH A GNRH AGONIST OF HIGH RISK NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)

International Family Members for US Patent 10,052,314

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013323861
Australia	2018206695
Australia	2020244431